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metalloproteinases (MMPs) (membrane type 1 MMP and MMP2) 
and neutral sphingomyelinase-2. This mitogenic signaling and sub-
sequent DNA synthesis are blocked in smooth muscle cells silenced 
for MMP2 or for neutral sphingomyelinase-2 by small interfering 
RNAs, in smooth muscle cells transfected with a vector coding for 
a dominant-negative form of membrane type 1 MMP, and after 
treatment by pharmacological inhibitors of MMPs (Ro28-2653) or 
neutral sphingomyelinase-2 (GW4869). To explore these findings 
in vivo, a model for human transplant vasculopathy, consisting of 
human mesenteric arterial segments grafted into severe combined 
immunodeficiency/beige mice, was developed. Mice injected weekly 
with monoclonal antibody against HLA class I developed neoin-
timal thickening of the grafted human arterial segment, whereas 
mice injected with an irrelevant antibody accepted the graft perma-
nently. Ro28-2653 and GW4869 also reduced the intimal thickening 
induced by anti-HLA antibodies in the in vivo model (Figure).
These clinically relevant data highlight a crucial role for metal-
loproteinases and neutral sphingomyelinase-2 in vasculopathy gen-
erated by a humoral immune response, opening new therapeutic 
perspectives for preventing this pathology, in addition to treatment 
with conventional immunosuppression. Further studies regarding 
the specificity and potential toxicity of this interesting MMP inhibi-
tor Ro28-2653 in the prevention of anti-HLA antibody-mediated 
vasculopathy are needed.
Marc De Broe
Measuring tissue sodium in patients
Kopp et al., Hypertension 2012; 59: 167–172; doi:10.1161/
HYPERTENSIONAHA.111.183517
It has long been known that Na+ intake has profound effects on 
extracellular fluid volume and cardiovascular homeostasis and 
disease. Although urinary Na+ excretion measurements can be 
an excellent indicator of Na+ intake, they are laborious and imprac-
tical when properly done. Moreover, measurements of total body 
Na+ content traditionally taken with exchangeable sodium are dif-
ficult and probably plagued by errors, as many assumptions are 
needed to interpret these measurements. Among those assump-
tions is the idea that, except in bone, all Na+ is in solution, mainly 
in the extracellular fluid volume or exchangeable with it, an idea 
that has recently been challenged. Provocative studies have pre-
sented evidence suggesting that organs such as the skin and muscle 
might store Na+ non-osmotically by its binding to proteoglycans. 
To measure tissue Na+ accurately, ashing of tissue and atomic 
absorption spectrometry are needed, and alternative methods 
would be welcomed. Thus, Kopp et al. used 23Na magnetic reso-
nance spectroscopy (23Na-MR) and imaging technique (23Na-
MRI) to quantify Na+ content in skeletal muscle and skin. They 
compared 23Na-MRI data with actual tissue Na+ content measured 
by chemical analysis in animal and human tissue. As shown in the 
Figure, there was an excellent agreement with both measurements. 
They then quantified tissue Na+ content in normal humans and in 
A key role for matrix 
metallo proteinases and neutral 
sphingomyelinase-2 in transplant 
vasculopathy triggered by  
anti-HLA antibody
Galvani et al., Circulation 2011; 124: 2725–2734; doi:10.1161/
CIRCULATIONAHA.111.021790
 Late outcome of organ transplants is impaired by transplant vas-
culopathy, mediated by immune and by nonimmune mechanisms 
such as ischemia/reperfusion, inflammation, viral infection, and 
hypertension. Transplant vasculopathy is characterized by progres-
sive neointimal hyperplasia leading to arterial stenosis and ischemic 
failure of the allograft. Galvani et al. tried to unravel the manner in 
which the humoral immune response, mimicked by W6/32 anti-
HLA antibody, contributes to transplant vasculopathy. Studies were 
performed in vitro on cultured human smooth muscle cells, ex vivo 
on human arterial segments, and in vivo in a model consisting of 
human arterial segments grafted into severe combined immunode-
ficiency/beige mice injected weekly with anti-HLA antibodies. The 
authors found that anti-HLA antibodies are mitogenic for smooth 
muscle cells through a signaling mechanism implicating matrix 
Ro28-2653 and GW4869 prevent neointimal thickening in 
human mesenteric segments grafted into severe combined 
immunodeficiency/beige mice treated with W6/32 monoclonal 
antibody. Intimal thickening of human mesenteric arteries grafted in 
severe combined immunodeficiency/beige immunodeficient mice, 
treated with irrelevant monoclonal antibody (mAb) (negative control) 
or W6/32 mAb (anti-HLA) and with or without Ro28-2653 or GW4869. 
Histological serial sections were stained, and intimal hyperplasia 
was estimated by histomorphological analysis. Top: Representative 
histological sections, with the neointimal area colorized pink (false 
color making the histomorphological evaluation easier), whereas 
the media and adventitia are colored blue. Measurements of intimal 
thickening were made every 200 mm along the length of the grafted 
artery (~8 mm long). Bottom: Serial histomorphometric analysis allowed 
reconstruction of a schematic representation of the vascular wall (blue) 
and intimal thickening (pink) of the grafted human mesenteric arteries 
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patients with primary aldosteronism and found a 29% increase in 
muscle Na+ in the latter. Interestingly, this tissue Na+ was mobi-
lized after successful treatment by adrenal adenoma surgery or at 
least 2 weeks of spironolactone treatment. The authors’ 23Na-MRI 
measurements suggest that the human tissue Na+ content is much 
more variable than expected. Thus, body Na+ stores can be moni-
tored noninvasively and longitudinally with 23Na-MRI.
After further refinements, this noninvasive quantitative diagnos-
tic approach may provide a valuable new tool for patient-oriented 
research on Na+ metabolism and disposition.
Juan Oliver
Renal dendritic cells adopt a 
proinflammatory phenotype in 
obstructive uropathy to activate  
T cells but do not directly 
contribute to fibrosis
Snelgrove et al., Am J Pathol 2012; 180: 91–103; doi:10.1016/j.ajpath.2011.09.039
The kidney contains a dense network of dendritic cells (DCs), 
which serves as a monitor of the local environment. The role of the 
DCs in renal diseases associated with progressive fibrosis remains 
unclear, partly because of the difficulties of clearly separating DCs 
from monocytes/macrophages, which show a considerable over-
lap in surface markers used for their identification. Snelgrove et 
al. evaluated the contribution of DCs to renal fibrosis in unilateral 
ureteral obstruction (UUO) as a model of accelerated renal fibro-
sis. Using mice with genetically engineered, fluorescently marked 
CD11c-positive DCs and multiphoton imaging, they studied in vivo 
the early local inflammatory events (day 3 of UUO) in the ligated 
kidney and clearly identified activation of the DCs. Phenotypic 
analysis suggested resident DC maturation in obstructed kidneys 
with increased CD11b and less F4/80 expression. The activated 
DCs showed enhanced antigen-presenting capacity with increased 
antigen-specific T-cell proliferation in vivo and ex vivo. However, 
conditional DC ablation at day 0, 2, or 4 did not attenuate fibrosis 
or apoptosis 7 days after UUO, and depletion at 7 days did not alter 
outcomes at day 14.
Therefore, renal DCs exhibit inflammatory morphological and 
functional characteristics after UUO and are more effective as anti-
gen-presenting cells. However, the activation of the resident DCs in 
the UUO model does not directly contribute to tubulointerstitial 
damage and fibrosis; this incriminates intrarenal macrophages as 
the major inflammatory cell type orchestrating these responses.
Detlef Schlöndorff
Liberal or restrictive transfusion in 
high-risk patients after hip surgery
Carson et al., N Engl J Med 2011; 365: 2453–2462; doi:10.1056/NEJMoa1012452
In the postoperative patient, the hemoglobin threshold below 
which the benefit of transfusion outweighs the risk and cost is not 
known. Carson et al. tested the hypothesis that a higher thresh-
old for blood transfusion would improve functional recovery and 
reduce morbidity and mortality. Patients aged 50 years or older 
undergoing surgical repair of a hip fracture with evidence of or 
risk factors for cardiovascular disease were randomized to liberal 
or restrictive transfusion strategies. Patients in the liberal-strategy 
group received at least one unit of packed red blood cells to main-
tain a hemoglobin level greater than 10 gm/dl. Patients in the 
restrictive-strategy group received a transfusion if signs or symp-
toms of anemia developed and at the discretion of the investigator 
if the hemoglobin level fell below 8 gm/dl. The primary outcome 
was death or inability to walk without assistance at 60 days. With 
respect to the primary end point, 35.2% and 34.7% of patients in the 
liberal- and restrictive-strategy groups, respectively, died or were 
unable to walk at 60 days. Cardiovascular events and other post-
operative complications were compared between groups without 
significant differences noted. Odds ratios for myocardial infarction, 
unstable angina, or in-hospital death were 0.82 (95% confidence 
interval (CI) 0.48–1.42); for congestive heart failure, 0.77 (95% CI 
0.39–1.50); and for transfer to the intensive care unit, 1.04 (95% CI 
0.53–2.05) in the liberal- as compared with the restrictive-strategy 
group. While recent controversy in the management of anemia in 
kidney disease has focused on chronic therapy and the impact of 
both target hemoglobin and erythrocyte-stimulating agents, this 
trial was able to a greater extent to isolate the target from the therapy 
required to achieve that target. In a large population of patients at 
higher risk for cardiovascular events, transfusion did not have any 
demonstrable impact on morbidity and mortality.
Although hemoglobin level is a measure of quality of care in end-
stage renal disease (ESRD), this trial suggests that as an intermediate 
outcome, it is not an appropriate surrogate in the postoperative 
population. Given the high-risk clinical period studied here and 
the short-term nature of the trial, it does not appear possible to 
extrapolate more from the trial to patients with ESRD. Perhaps, 
however, we should assume a greater degree of skepticism regarding 
the validity of hemoglobin as an intermediate outcome.
Lynda Szczech
Muscle Na+ concentration. Left: In rat muscle samples, Na+ content 
was measured by magnetic resonance (MR) spectrometry or by 
chemical analysis (atomic absorption spectrometry) after ashing. 
Deoxycorticosterone acetate (DOCA) plus high salt increased muscle Na+ 
content; MR spectrometry detected this increase in the same rats. Right: 
Relationship between muscle Na+ content measured noninvasively with 
MR spectrometry (abscissa) and chemical analysis (ordinate) in the same 
animal. *P < 0.05 versus tap water; †P < 0.05 versus control. AAS, ashing; HS, 
high salt; LS, low salt.
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